| 764328 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
585 LIGHT (TNFSF14) co-stimulation enhances myeloid cell activation and anti-tumor immunity in the setting of PD-1 and TIGIT checkpoint blockade |
2021-11-01 |
10.1136/jitc-2021-sitc2021.585 |
Fromm George, Yoo Kyung Jin, Johannes Kellsey, Shuptrine Casey, Opheim Zach, Patel Arpita, Andreasen Haley, Miriyala Jaya, Silva Suresh De, Schreiber Taylor |
| 764327 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
584 Powerful synergistic effects of a STING agonist and the IL-2 superkine, H9, in eliciting NK and T cell responses against MHC I- and MHC I+ tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.584 |
Wolf Natalie, Blaj Cristina, Picton Lora, Snyder Gail, Zhang Li, Nicolai Christopher, Ndubaku Chudi, Gauthier Kelsey Sivick, McWhirter Sarah, Christopher Garcia K, Raulet David |
| 764326 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
583 Exploring the potential of T cell acute lymphoblastic leukemia (T-ALL) for generating leukemia-specific T cell responses that can be therapeutically harnessed with immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.583 |
Triplett Todd, Rios Joshua, Somma Alexander, Church Sarah, North Khrystyna, White Andrew, Holay Nisha, Weinberg Andrew |
| 764325 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
578 CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines |
2021-11-01 |
10.1136/jitc-2021-sitc2021.578 |
Sultan Hussein, Moynihan Kelly, Song Yuang, Ameh Samuel, Schumacher Ton, Yeung Yik Andy, Djuretic Ivana, Schreiber Robert |
| 764324 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
577 Non-clinical efficacy, pharmacokinetics, and pharmacodynamics of a novel bi-functional anti-CD73-TGFβRII-trap molecule in combination with immune checkpoint therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.577 |
Stinson Susanna, He Jianhua, Kim Kyung-Hoon, Yang Becky, Zavodovskaya Marianna, Yi Ping, Campigotto Federico, Sobczyk Monika, Dave Rutwij, Carr Brian, Mah In Kyoung, Zaboli Shiva, Brodbeck Jens, Turner Scott, Barry Vivian, Boyd Kelli, Fantin Valeria |
| 764323 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive |
2021-11-01 |
10.1136/jitc-2021-sitc2021.242 |
Bai Haiyan, Padrón Álvaro, Deng Yilun, Kornepati Anand, Polusani Srikanth, Kari Suresh, Murray Clare, Garcia Myrna, Reyes Ryan, Ji Niannian, Gupta Harshita, Hart Matthew, Curiel Tyler |
| 764322 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
240 Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling |
2021-11-01 |
10.1136/jitc-2021-sitc2021.240 |
Moutafi Myrto, Martinez-Morilla Sandra, Divakar Prajan, Vathiotis Ioannis, Gavrielatou Niki, Aung Thazin, Yaghoobi Vesal, Fernandez Aileen, Fraile Jon Zugazagoitia, Schalper Kurt, Rimm David |
| 764321 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
238 Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.238 |
Hong Seung Pyo, Kim Min Jeong, Belette Allison, Oh Youjin, Cho Sukjoo, Chae Young Kwang |
| 764320 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
237 Infectious complications in patients with non-small cell lung cancer treated with anti-PD(L)1 immune checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.237 |
Guo Matthew, Balaji Aanika, Murray Joseph, Reuss Joshua, Steinke Seema Mehta, Naidoo Jarushka |
| 764319 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
236 Predictors of ICI renal toxicity: a pathological approach |
2021-11-01 |
10.1136/jitc-2021-sitc2021.236 |
Abudayyeh Ala, Suo Liye, Lin Heather, Mamlouk Omar, Yee Cassian, Tchakarov Amanda, Lin Jamie |
